Spruce Biosciences (SPRB) Fireside Chat - SPRUCE BIOSCIENCES INC

Explicit Guidance:

• BLA Submission: Management expects to submit a Biologics License Application (BLA) for TA-ERT in the fourth quarter of the current year, describing the timeline as "moving very swiftly."
• Revenue/Patient Volume: Will not provide specific revenue or patient count guidance until the pre-launch window. However, management notes that current identification of patients in the Expanded Access Program (EAP) has "far exceeded" projected needs for Year 1 of commercialization.
• Pricing Corridor: Projects a reasonable pricing corridor of $1 million to $2 million per patient per year for the fixed-dose product, noting that weight-based analogs currently range up to $2.5–$2.8 million.

Business-Segment Outlook:

• Product Launch & Demand: Anticipates a commercial launch next year with "significant demand." Management notes that Ultragenyx's recent MPS3A approval is creating "noise" in the market, likely leading to increased identification of MPS3B patients and accelerated adoption of newborn screening efforts.
• Pipeline & Backlog: Management projects ~20 new patients annually in the U.S. (based on 0.5% incidence per 100,000 live births) and estimates a total addressable market of approximately 450 patients in the U.S., with a potentially larger global opportunity.
• Geographic Expansion: Plans to commercialize globally, leveraging local distributors and licensing agreements in ex-U.S. markets to navigate competitive pricing pressures and Most Favored Nation (MFN) clauses.

Market and Competitive Outlook:

• Competitive Positioning: Anticipates a "full approval" pathway similar to Ultragenyx's recent MPS3A approval, leveraging a clinical package that includes robust natural history data (conducted by Biomarin) and modeling to adjust for baseline imbalances.
• Treatment Strategy: No upper age limit for therapy; treatment decisions will be physician/caregiver driven based on disease stage. Management expects high willingness among families to accept therapy to halt disease progression, even in adult patients.
• Pricing Environment: Acknowledges "competitive pressure on pricing" globally but intends to set pricing based on the fixed-dose nature of the therapy, distinct from weight-based competitors.

Macro / Industry Outlook:

• Regulatory Landscape: Management expects the FDA to accept heparan sulfate reduction as a "reasonably likely surrogate endpoint" for clinical benefit, mirroring the approach taken for the MPS2 (Hunter) product approval.
• Diagnostic Infrastructure: Anticipates positive industry-wide impact from new approvals (Ultragenyx's MPS3A and Novartis's Mepsevii/Fabrazyme) driving newborn screening initiatives and improved ICD-10 coding specificity for MPS3 subtypes.

Strategic Initiatives:

• Manufacturing: Completed manufacturing of Drug Substance (TS) and Drug Product (DP) for PPQ-2; plans to fill PPQ-2 drug product later this quarter. Confirms alignment with FDA on including PPQ-2 materials in the review.
• Partnerships & Patient Access: Partnered with patient advocacy groups (CURE San Felipe, National MPS Society) to fundraise and provide product for the Expanded Access Program.
• Commercial Infrastructure: Plans to engage with 15 lysosomal storage disease centers of excellence across the U.S. to prepare for launch.
• Post-Approval Commitments: While a full approval may lower the need for a confirmatory study, management expects the FDA may request a patient registry to capture long-term follow-up data, though they possess extensive existing follow-up data supporting durable efficacy.

Risks and Headwinds to Outlook:

• Supply Chain Disruption: Addresses potential labor strikes at Samsung Biologics (manufacturer). Management states these are typically resolved without major impact due to the facility's extra workforce capacity and the company's completed PPQ-2 manufacturing; expects no material impact on the BLA timeline.
• Diagnostic Precision: Current ICD-10 coding lacks segmentation for MPS3 subtypes (A, B, C, D), creating imprecision in patient identification and claims database analysis prior to launch.
• Regulatory Pathway Uncertainty: While confident in the data package, the final determination of full vs. accelerated approval remains with the FDA, though a full approval is preferred to eliminate confirmatory study requirements.

Management Tone on the Future:

• Confidence Level: Highly confident and positive. Uses descriptors such as "very positive," "fairly robust package," and "things are moving very swiftly."
• Strategic Outlook: Expresses strong optimism regarding market demand, noting that identified patient volume exceeds Year 1 projections and that the competitive landscape (Ultragenyx approval) is a catalyst for broader disease awareness rather than a threat.

Miscellaneous:

• Clinical Endpoints: The clinical package submitted will span cognition, adaptive behavior, motor communication, MRI results, and peripheral benefits (clearance of heparan sulfate from liver and spleen), with specific emphasis on "profound effect sizes" and model data adjustments.
• Patient Outcomes: Management cites examples of treated children achieving normal developmental milestones (speaking three languages, attending regular school), contrasting sharply with the natural history of untreated pediatric dementia.